Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenalidomide - Starton Therapeutics

Next Previous
Drug Profile

Lenalidomide - Starton Therapeutics

Alternative Names: CMIO-LLD; STAR LLD programme; STAR-LLD; STAR-LLD SC

Latest Information Update: 08 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ChemioCare
  • Developer Starton Therapeutics
  • Class 2 ring heterocyclic compounds; Antineoplastics; Imides; Isoindoles; Piperidones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cell proliferation inhibitors; Immunomodulators; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Research Haematological malignancies
  • No development reported Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Myelodysplastic syndromes

Most Recent Events

  • 24 Jun 2025 Early research in Haematological malignancies in USA (PO)
  • 28 May 2025 No recent reports of development identified for phase-I development in Multiple-myeloma(In volunteers) in Netherlands (SC, Infusion)
  • 25 Apr 2025 Pharmacokinetics and pharmacodynamics data from a phase I/II trial in Multiple-myeloma presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top